Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countries
暂无分享,去创建一个
C. Porta | M. Neary | J. Bellmunt | J. McCaffrey | D. Castellano | J. Wagstaff | A. Levy | R. Hawkins | R. McDermott | P. Nathan | F. Vekeman | M. Duh | P. Donnellan | José Diaz | F. Mehmud | A. Lévy